Hookipa Pharma Inc. Stock News

The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.

Hookipa Pharma Inc (NASDAQ: HOOK) reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data were

NEW YORK and VIENNA, Austria, June 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK and VIENNA, Austria, April 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav

HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2020 Results - Earnings Call Transcript

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 15.00% over the past year to ($0.46), which beat the es

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncolog

NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,